<H1>Chapter DOI: 10.1007/978-1-60327-829-4_22<br/>Cited-By Count: 0</H1><table border="1" width="30%"><tr><td>Total References</td><td>110</td></tr><tr><td>Springer references</td><td>6</td></tr><tr><td>Non Springer references</td><td>104</td></tr><tr><td>BibStructured Count</td><td width="10%">110</td></tr><tr><td>BibUnstructured Count</td><td width="10%">0</td></tr><tr><td>DOI already available in SpringerLink</td><td>0</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>70</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>1</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>6</td></tr><tr><td>DOI Obtained For Non Springer</td><td>64</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>70</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>57</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1_22</td><td>BibArticle</td><td>Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8&#8211;31.</td><td><a href=http://dx.doi.org/10.3322/canjclin.49.1.8>10.3322/canjclin.49.1.8</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Year, FirstPage, Author_FamilyName_2, VolumeID, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR2_22</td><td>BibArticle</td><td>Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004;64:9209&#8211;16.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-04-2442>10.1158/0008-5472.CAN-04-2442</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, VolumeID, FirstPage, Year, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR3_22</td><td>BibArticle</td><td>Moul JW, Lipo DR. Prostate cancer in the late 1990s: hormone refractory disease options. Urol Nurs 1999;19:125&#8211;31; quiz 32&#8211;3.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR4_22</td><td>BibArticle</td><td>Augat P, Simon U, Liedert A, Claes L. Mechanics and mechano-biology of fracture healing in normal and osteoporotic bone. Osteoporos Int 2005;16(Suppl 2):S36&#8211;43.</td><td><a href=http://dx.doi.org/10.1007/s00198-004-1728-9>10.1007/s00198-004-1728-9</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, ArticleTitle, Author_FamilyName_1, Author_FamilyName_2, VolumeID</td><td>CrossRef</td></tr><tr><td>CR5_22</td><td>BibArticle</td><td>Hasegawa K, Turner CH, Burr DB. Contribution of collagen and mineral to the elastic anisotropy of bone. Calcif Tissue Int 1994;55:381&#8211;6.</td><td><a href=http://dx.doi.org/10.1007/BF00299319>10.1007/BF00299319</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Year, FirstPage, Author_FamilyName_2, VolumeID, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR6_22</td><td>BibArticle</td><td>Pinero GJ, Farach-Carson MC, Devoll RE, Aubin JE, Brunn JC, Butler WT. Bone matrix proteins in osteogenesis and remodelling in the neonatal rat mandible as studied by immunolocalization of osteopontin, bone sialoprotein, alpha 2HS-glycoprotein and alkaline phosphatase. Arch Oral Biol 1995;40:145&#8211;55.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR7_22</td><td>BibArticle</td><td>Romanowski R, Jundt G, Termine JD, von der Mark K, Schulz A. Immunoelectron microscopy of osteonectin and type I collagen in osteoblasts and bone matrix. Calcif Tissue Int 1990;46:353&#8211;60.</td><td><a href=http://dx.doi.org/10.1007/BF02554964>10.1007/BF02554964</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, FirstPage, Year, VolumeID, Author_FamilyName_2, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR8_22</td><td>BibArticle</td><td>Oguma H, Murakami G, Takahashi-Iwanaga H, Aoki M, Ishii S. Early anchoring collagen fibers at the bone-tendon interface are conducted by woven bone formation: light microscope and scanning electron microscope observation using a canine model. J Orthop Res 2001;19:873&#8211;80.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1016/S0736-0266(01)00021-3>10.1016/S0736-0266(01)00021-3</a></td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_2, Author_FamilyName_1, Year, FirstPage</td><td>CrossRef</td></tr><tr><td>CR9_22</td><td>BibArticle</td><td>Marotti G, Muglia MA, Palumbo C. Collagen texture and osteocyte distribution in lamellar bone. Ital J Anat Embryol 1995;100(Suppl 1):95&#8211;102.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR10_22</td><td>BibArticle</td><td>Currey JD. The many adaptations of bone. J Biomech 2003;36:1487&#8211;95.</td><td><a href=http://dx.doi.org/10.1016/S0021-9290(03)00124-6>10.1016/S0021-9290(03)00124-6</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Year, FirstPage, VolumeID, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR11_22</td><td>BibArticle</td><td>Currey JD. Tensile yield in compact bone is determined by strain, post-yield behaviour by mineral content. J Biomech 2004;37:549&#8211;56.</td><td><a href=http://dx.doi.org/10.1016/j.jbiomech.2003.08.008>10.1016/j.jbiomech.2003.08.008</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, FirstPage, Year, VolumeID, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR12_22</td><td>BibArticle</td><td>Schinke T, Karsenty G. Characterization of Osf1, an osteoblast-specific transcription factor binding to a critical cis-acting element in the mouse Osteocalcin promoters. J Biol Chem 1999;274:30182&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR13_22</td><td>BibArticle</td><td>Ducy P. Cbfa1: a molecular switch in osteoblast biology. Dev Dyn 2000;219:461&#8211;71.</td><td><a href=http://dx.doi.org/10.1002/1097-0177(2000)9999:9999%3C::AID-DVDY1074%3E3.0.CO;2-C>10.1002/1097-0177(2000)9999:9999%3C::AID-DVDY1074%3E3.0.CO;2-C</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, VolumeID, Year, FirstPage, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR14_22</td><td>BibArticle</td><td>Vaananen HK, Zhao H, Mulari M, Halleen JM. The cell biology of osteoclast function. J Cell Sci 2000;113 (Pt 3):377&#8211;81.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR15_22</td><td>BibArticle</td><td>Uy HL, Mundy GR, Boyce BF, et al. Tumor necrosis factor enhances parathyroid hormone-related protein- induced hypercalcemia and bone resorption without inhibiting bone formation in vivo. Cancer Res 1997;57:3194&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR16_22</td><td>BibArticle</td><td>Lum L, Wong BR, Josien R, et al. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)- converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 1999;274:13613&#8211;8.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR17_22</td><td>BibArticle</td><td>Shalhoub V, Elliott G, Chiu L, et al. Characterization of osteoclast precursors in human blood. Br J Haematol 2000;111:501&#8211;12.</td><td><a href=http://dx.doi.org/10.1046/j.1365-2141.2000.02379.x>10.1046/j.1365-2141.2000.02379.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_2, Author_FamilyName_1, ArticleTitle, FirstPage, Year</td><td>CrossRef</td></tr><tr><td>CR18_22</td><td>BibArticle</td><td>Hofbauer LC, Heufelder AE. The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. Arthritis Rheum 2001;44:253&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR19_22</td><td>BibArticle</td><td>Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309&#8211;19.</td><td><a href=http://dx.doi.org/10.1016/S0092-8674(00)80209-3>10.1016/S0092-8674(00)80209-3</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>JournalTitle, Author_FamilyName_1, VolumeID, Author_FamilyName_2, FirstPage, Year, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR20_22</td><td>BibArticle</td><td>Tsuda E, Goto M, Mochizuki S, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997;234:137&#8211;42.</td><td><a href=http://dx.doi.org/10.1006/bbrc.1997.6603>10.1006/bbrc.1997.6603</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_2, Author_FamilyName_1, ArticleTitle, FirstPage, Year</td><td>CrossRef</td></tr><tr><td>CR21_22</td><td>BibArticle</td><td>Nagai M, Sato N. Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast differentiation factor regulates osteoclast formation. Biochem Biophys Res Commun 1999;257:719&#8211;23.</td><td><a href=http://dx.doi.org/10.1006/bbrc.1999.0524>10.1006/bbrc.1999.0524</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, FirstPage, ArticleTitle, Author_FamilyName_1, Author_FamilyName_2, VolumeID</td><td>CrossRef</td></tr><tr><td>CR22_22</td><td>BibArticle</td><td>Hofbauer LC, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 1998;250:776&#8211;81.</td><td><a href=http://dx.doi.org/10.1006/bbrc.1998.9394>10.1006/bbrc.1998.9394</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, VolumeID, Author_FamilyName_2, Year, FirstPage, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR23_22</td><td>BibArticle</td><td>Roodman GD. Cell biology of the osteoclast. Exp Hematol 1999;27:1229&#8211;41.</td><td><a href=http://dx.doi.org/10.1016/S0301-472X(99)00061-2>10.1016/S0301-472X(99)00061-2</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, FirstPage, Year, VolumeID, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR24_22</td><td>BibArticle</td><td>Katunuma N. Mechanism and regulation of bone resorption by osteoclasts. Curr Top Cell Regul 1997;35:179&#8211;92.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1016/S0070-2137(97)80008-8>10.1016/S0070-2137(97)80008-8</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, Year, FirstPage</td><td>CrossRef</td></tr><tr><td>CR25_22</td><td>BibArticle</td><td>Kiviranta R, Morko J, Uusitalo H, Aro HT, Vuorio E, Rantakokko J. Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K. J Bone Miner Res 2001;16:1444&#8211;52.</td><td><a href=http://dx.doi.org/10.1359/jbmr.2001.16.8.1444>10.1359/jbmr.2001.16.8.1444</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>JournalTitle, Author_FamilyName_1, Author_FamilyName_2, VolumeID, Year, FirstPage, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR26_22</td><td>BibArticle</td><td>Gowen M, Lazner F, Dodds R, et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 1999;14:1654&#8211;63.</td><td><a href=http://dx.doi.org/10.1359/jbmr.1999.14.10.1654>10.1359/jbmr.1999.14.10.1654</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Year, ArticleTitle, JournalTitle, Author_FamilyName_1, VolumeID, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR27_22</td><td>BibArticle</td><td>Lee BS, Holliday LS, Ojikutu B, Krits I, Gluck SL. Osteoclasts express the B2 isoform of vacuolar H(+)-ATPase intracellularly and on their plasma membranes. Am J Physiol 1996;270:C382&#8211;8.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR28_22</td><td>BibArticle</td><td>Lehenkari P, Hentunen TA, Laitala-Leinonen T, Tuukkanen J, Vaananen HK. Carbonic anhydrase II plays a major role in osteoclast differentiation and bone resorption by effecting the steady state intracellular pH and Ca<Superscript>2+</Superscript>. Exp Cell Res 1998;242:128&#8211;37.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1006/excr.1998.4071>10.1006/excr.1998.4071</a></td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_2, Author_FamilyName_1, FirstPage, Year</td><td>CrossRef</td></tr><tr><td>CR29_22</td><td>BibArticle</td><td>Lalande A, Roux S, Denne MA, et al. Indapamide, a thiazide-like diuretic, decreases bone resorption in vitro. J Bone Miner Res 2001;16:361&#8211;70.</td><td><a href=http://dx.doi.org/10.1359/jbmr.2001.16.2.361>10.1359/jbmr.2001.16.2.361</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, FirstPage, ArticleTitle, JournalTitle, Author_FamilyName_1, VolumeID, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR30_22</td><td>BibArticle</td><td>Rodan GA. The development and function of the skeleton and bone metastases. Cancer 2003;97:726&#8211;32.</td><td><a href=http://dx.doi.org/10.1002/cncr.11147>10.1002/cncr.11147</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Year, FirstPage, VolumeID, JournalTitle, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR31_22</td><td>BibArticle</td><td>Munk PL, Poon PY, O&#8217;Connell JX, et al. Osteoblastic metastases from breast carcinoma with false-negative bone scan. Skeletal Radiol 1997;26:434&#8211;7.</td><td><a href=http://dx.doi.org/10.1007/s002560050262>10.1007/s002560050262</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, VolumeID, Author_FamilyName_2, FirstPage, Year, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR32_22</td><td>BibArticle</td><td>Roudier M, Sherrard D, True L, et al. Heterogenous bone histomorphometric patterns in metastatic prostate cancer. J Bone Miner Res 2000;15S1:S567.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR33_22</td><td>BibArticle</td><td>Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000;88:2989&#8211;94.</td><td><a href=http://dx.doi.org/10.1002/1097-0142(20000615)88:12+%3C2989::AID-CNCR14%3E3.3.CO;2-H>10.1002/1097-0142(20000615)88:12+%3C2989::AID-CNCR14%3E3.3.CO;2-H</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, VolumeID, Author_FamilyName_1, JournalTitle, ArticleTitle, Year, FirstPage</td><td>CrossRef</td></tr><tr><td>CR34_22</td><td>BibArticle</td><td>Hullinger TG, Taichman RS, Linseman DA, Somerman MJ. Secretory products from PC-3 and MCF-7 tumor cell lines upregulate osteopontin in MC3T3-E1 cells. J Cell Biochem 2000;78:607&#8211;16.</td><td><a href=http://dx.doi.org/10.1002/1097-4644(20000915)78:4%3C607::AID-JCB10%3E3.0.CO;2-F>10.1002/1097-4644(20000915)78:4%3C607::AID-JCB10%3E3.0.CO;2-F</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, FirstPage, Year, Author_FamilyName_2, VolumeID, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR35_22</td><td>BibArticle</td><td>Lalich M, McNeel DG, Wilding G, Liu G. Endothelin receptor antagonists in cancer therapy. Cancer Invest 2007;25:785&#8211;94.</td><td><a href=http://dx.doi.org/10.1080/07357900701522588>10.1080/07357900701522588</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, Author_FamilyName_2, VolumeID, Year, FirstPage, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR36_22</td><td>BibArticle</td><td>Cornish J, Callon KE, Lin C, Xiao C, Moseley JM, Reid IR. Stimulation of osteoblast proliferation by C-terminal fragments of parathyroid hormone-related protein. J Bone Miner Res 1999;14:915&#8211;22.</td><td><a href=http://dx.doi.org/10.1359/jbmr.1999.14.6.915>10.1359/jbmr.1999.14.6.915</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_2, JournalTitle, Author_FamilyName_1, ArticleTitle, FirstPage, Year</td><td>CrossRef</td></tr><tr><td>CR37_22</td><td>BibArticle</td><td>Rabbani SA, Gladu J, Mazar AP, Henkin J, Goltzman D. Induction in human osteoblastic cells (SaOS2) of the early response genes fos, jun, and myc by the amino terminal fragment (ATF) of urokinase. J Cell Physiol 1997;172:137&#8211;45.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR38_22</td><td>BibArticle</td><td>Honore P, Luger NM, Sabino MA, et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 2000;6:521&#8211;8.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR39_22</td><td>BibArticle</td><td>Chiao JW, Moonga BS, Yang YM, et al. Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br J Cancer 2000;83:360&#8211;5.</td><td><a href=http://dx.doi.org/10.1054/bjoc.2000.1261>10.1054/bjoc.2000.1261</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Year, FirstPage, Author_FamilyName_2, VolumeID, JournalTitle, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR40_22</td><td>BibArticle</td><td>Lin DL, Tarnowski CP, Zhang J, et al. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 2001;47:212&#8211;21.</td><td><a href=http://dx.doi.org/10.1002/pros.1065>10.1002/pros.1065</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, VolumeID, Author_FamilyName_2, FirstPage, Year, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR41_22</td><td>BibArticle</td><td>Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001;107:1235&#8211;44.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1172/JCI11685>10.1172/JCI11685</a></td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Year, Author_FamilyName_1, VolumeID, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR42_22</td><td>BibArticle</td><td>Brown JM, Corey E, Lee ZD, et al. Osteoprotegerin and rank ligand expression in prostate cancer. Urology 2001;57:611&#8211;6.</td><td><a href=http://dx.doi.org/10.1016/S0090-4295(00)01122-5>10.1016/S0090-4295(00)01122-5</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_2, JournalTitle, Author_FamilyName_1, ArticleTitle, FirstPage, Year</td><td>CrossRef</td></tr><tr><td>CR43_22</td><td>BibArticle</td><td>Perez-Martinez FC, Alonso V, Sarasa JL, et al. Receptor activator of nuclear factor-kappaB ligand (RANKL) as a novel prognostic marker in prostate carcinoma. Histol Histopathol 2008;23:709&#8211;15.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR44_22</td><td>BibArticle</td><td>Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani SA. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 2006;107:289&#8211;98.</td><td><a href=http://dx.doi.org/10.1002/cncr.21978>10.1002/cncr.21978</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, JournalTitle, Author_FamilyName_2, VolumeID, Year, FirstPage, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR45_22</td><td>BibArticle</td><td>Brown JM, Vessella RL, Kostenuik PJ, Dunstan CR, Lange PH, Corey E. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res 2001;7:2977&#8211;83.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR46_22</td><td>BibArticle</td><td>Jung K, Stephan C, Semjonow A, Lein M, Schnorr D, Loening SA. Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. J Urol 2003;170:2302&#8211;5.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR47_22</td><td>BibArticle</td><td>Kiefer JA, Vessella RL, Quinn JE, et al. The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. Clin Exp Metastasis 2004;21:381&#8211;7.</td><td><a href=http://dx.doi.org/10.1007/s10585-004-2869-0>10.1007/s10585-004-2869-0</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Year, FirstPage, VolumeID, Author_FamilyName_2, Author_FamilyName_1, JournalTitle</td><td>CrossRef</td></tr><tr><td>CR48_22</td><td>BibArticle</td><td>Zhang J, Dai J, Yao Z, Lu Y, Dougall W, Keller ET. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res 2003;63:7883&#8211;90.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR49_22</td><td>BibArticle</td><td>Stearns ME, Wang M. Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. Invasion Metastasis 1996;16:116&#8211;31.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR50_22</td><td>BibArticle</td><td>John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 2001;7:14&#8211;23.</td><td><a href=http://dx.doi.org/10.1007/BF03032599>10.1007/BF03032599</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, Author_FamilyName_2, VolumeID, Year, FirstPage, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR51_22</td><td>BibArticle</td><td>Festuccia C, Bologna M, Vicentini C, et al. Increased matrix metalloproteinase-9 secretion in short-term tissue cultures of prostatic tumor cells. Int J Cancer 1996;69:386&#8211;93.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1002/(SICI)1097-0215(19961021)69:5%3C386::AID-IJC6%3E3.3.CO;2-A>10.1002/(SICI)1097-0215(19961021)69:5%3C386::AID-IJC6%3E3.3.CO;2-A</a></td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Year, Author_FamilyName_1, VolumeID, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR52_22</td><td>BibArticle</td><td>Festuccia C, Giunciuglio D, Guerra F, et al. Osteoblasts modulate secretion of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) in human prostate cancer cells promoting migration and matrigel invasion. Oncol Res 1999;11:17&#8211;31.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR53_22</td><td>BibArticle</td><td>Nabha SM, dos Santos EB, Yamamoto HA, et al. Bone marrow stromal cells enhance prostate cancer cell invasion through type I collagen in an MMP-12 dependent manner. Int J Cancer 2008;122:2482&#8211;90.</td><td><a href=http://dx.doi.org/10.1002/ijc.23431>10.1002/ijc.23431</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Year, ArticleTitle, Author_FamilyName_1, VolumeID</td><td>CrossRef</td></tr><tr><td>CR54_22</td><td>BibArticle</td><td>Duivenvoorden WC, Hirte HW, Singh G. Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells. Invasion Metastasis 1997;17:312&#8211;22.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR55_22</td><td>BibArticle</td><td>Sanchez-Sweatman OH, Orr FW, Singh G. Human metastatic prostate PC3 cell lines degrade bone using matrix metalloproteinases. Invasion Metastasis 1998;18:297&#8211;305.</td><td><a href=http://dx.doi.org/10.1159/000024522>10.1159/000024522</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_2, JournalTitle, Author_FamilyName_1, ArticleTitle, FirstPage</td><td>CrossRef</td></tr><tr><td>CR56_22</td><td>BibArticle</td><td>Stratton MS, Sirvent H, Udayakumar TS, Nagle RB, Bowden GT. Expression of the matrix metalloproteinase promatrilysin in coculture of prostate carcinoma cell lines. Prostate 2001;48:206&#8211;9.</td><td><a href=http://dx.doi.org/10.1002/pros.1099>10.1002/pros.1099</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, FirstPage, ArticleTitle, Author_FamilyName_1, Author_FamilyName_2, VolumeID</td><td>CrossRef</td></tr><tr><td>CR57_22</td><td>BibArticle</td><td>Smith PC, Hobish A, Lin D, Culig Z, Keller ET. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 2001;12:33&#8211;40.</td><td><a href=http://dx.doi.org/10.1016/S1359-6101(00)00021-6>10.1016/S1359-6101(00)00021-6</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, VolumeID, Year, FirstPage, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR58_22</td><td>BibArticle</td><td>Lee J, Weber M, Mejia S, Bone E, Watson P, Orr W. A matrix metalloproteinase inhibitor, batimastat, retards the development of osteolytic bone metastases by MDA-MB-231 human breast cancer cells in Balb C nu/nu mice. Eur J Cancer 2001;37:106&#8211;13.</td><td><a href=http://dx.doi.org/10.1016/S0959-8049(00)00363-4>10.1016/S0959-8049(00)00363-4</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, Author_FamilyName_2, VolumeID, FirstPage, Year, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR59_22</td><td>BibArticle</td><td>Nemeth JA, Yousif R, Herzog M, et al. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 2002;94:17&#8211;25.</td><td><a href=http://dx.doi.org/10.1093/jnci/94.1.17>10.1093/jnci/94.1.17</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_1, ArticleTitle, FirstPage, Year</td><td>CrossRef</td></tr><tr><td>CR60_22</td><td>BibArticle</td><td>Stearns ME, Wang M. Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice. Clin Exp Metastasis 1998;16:693&#8211;702.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR61_22</td><td>BibArticle</td><td>Strewler GJ. The physiology of parathyroid hormone-related protein. N Engl J Med 2000;342:177&#8211;85.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR62_22</td><td>BibArticle</td><td>Iwamura M, Abrahamsson PA, Foss KA, Wu G, Cockett AT, Deftos LJ. Parathyroid hormone-related protein: a potential autocrine growth regulator in human prostate cancer cell lines. Urology 1994;43:675&#8211;9.</td><td><a href=http://dx.doi.org/10.1016/0090-4295(94)90183-X>10.1016/0090-4295(94)90183-X</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, JournalTitle, VolumeID, FirstPage, Year, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR63_22</td><td>BibArticle</td><td>Deftos LJ. Prostate carcinoma: production of bioactive factors. Cancer 2000;88:3002&#8211;8.</td><td><a href=http://dx.doi.org/10.1002/1097-0142(20000615)88:12+%3C3002::AID-CNCR16%3E3.0.CO;2-1>10.1002/1097-0142(20000615)88:12+%3C3002::AID-CNCR16%3E3.0.CO;2-1</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, JournalTitle, Author_FamilyName_1, ArticleTitle, FirstPage, Year</td><td>CrossRef</td></tr><tr><td>CR64_22</td><td>BibArticle</td><td>Iwamura M, di Sant&#8217;Agnese PA, Wu G, et al. Immunohistochemical localization of parathyroid hormone-related protein in human prostate cancer. Cancer Res 1993;53:1724&#8211;6.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR65_22</td><td>BibArticle</td><td>Asadi F, Farraj M, Sharifi R, Malakouti S, Antar S, Kukreja S. Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia. Hum Pathol 1996;27:1319&#8211;23.</td><td><a href=http://dx.doi.org/10.1016/S0046-8177(96)90344-5>10.1016/S0046-8177(96)90344-5</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, VolumeID, Author_FamilyName_1, ArticleTitle, FirstPage, Year</td><td>CrossRef</td></tr><tr><td>CR66_22</td><td>BibArticle</td><td>Iwamura M, Gershagen S, Lapets O, et al. Immunohistochemical localization of parathyroid hormone-related protein in prostatic intraepithelial neoplasia. Hum Pathol 1995;26:797&#8211;801.</td><td><a href=http://dx.doi.org/10.1016/0046-8177(95)90230-9>10.1016/0046-8177(95)90230-9</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_2, Author_FamilyName_1, ArticleTitle, Year, FirstPage</td><td>CrossRef</td></tr><tr><td>CR67_22</td><td>BibArticle</td><td>Dougherty KM, Blomme EA, Koh AJ, et al. Parathyroid hormone-related protein as a growth regulator of prostate carcinoma. Cancer Res 1999;59:6015&#8211;22.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR68_22</td><td>BibArticle</td><td>Iddon J, Bundred NJ, Hoyland J, et al. Expression of parathyroid hormone-related protein and its receptor in bone metastases from prostate cancer. J Pathol 2000;191:170&#8211;4.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1002/(SICI)1096-9896(200006)191:2%3C170::AID-PATH620%3E3.3.CO;2-8>10.1002/(SICI)1096-9896(200006)191:2%3C170::AID-PATH620%3E3.3.CO;2-8</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, VolumeID, Author_FamilyName_1, FirstPage, Year</td><td>CrossRef</td></tr><tr><td>CR69_22</td><td>BibArticle</td><td>Kremer R, Goltzman D, Amizuka N, Webber MM, Rhim JS. ras Activation of human prostate epithelial cells induces overexpression of parathyroid hormone-related peptide. Clin Cancer Res 1997;3:855&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR70_22</td><td>BibArticle</td><td>Peehl DM, Edgar MG, Cramer SD, Deftos LJ. Parathyroid hormone-related protein is not an autocrine growth factor for normal prostatic epithelial cells. Prostate 1997;31:47&#8211;52.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1002/(SICI)1097-0045(19970401)31:1%3C47::AID-PROS8%3E3.3.CO;2-D>10.1002/(SICI)1097-0045(19970401)31:1%3C47::AID-PROS8%3E3.3.CO;2-D</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, VolumeID, Author_FamilyName_2, Year, FirstPage</td><td>CrossRef</td></tr><tr><td>CR71_22</td><td>BibArticle</td><td>Blomme EA, Dougherty KM, Pienta KJ, Capen CC, Rosol TJ, McCauley LK. Skeletal metastasis of prostate adenocarcinoma in rats: morphometric analysis and role of parathyroid hormone-related protein. Prostate 1999;39:187&#8211;97.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1002/(SICI)1097-0045(19990515)39:3%3C187::AID-PROS7%3E3.3.CO;2-V>10.1002/(SICI)1097-0045(19990515)39:3%3C187::AID-PROS7%3E3.3.CO;2-V</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, Author_FamilyName_2, VolumeID, FirstPage, Year</td><td>CrossRef</td></tr><tr><td>CR72_22</td><td>BibArticle</td><td>Perez-Martinez FC, Alonso V, Sarasa JL, et al. Immunohistochemical analysis of low-grade and high-grade prostate carcinoma: relative changes of parathyroid hormone-related protein and its parathyroid hormone 1 receptor, osteoprotegerin and receptor activator of nuclear factor-kB ligand. J Clin Pathol 2007;60:290&#8211;4.</td><td><a href=http://dx.doi.org/10.1136/jcp.2006.037853>10.1136/jcp.2006.037853</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_2, Author_FamilyName_1, ArticleTitle, FirstPage</td><td>CrossRef</td></tr><tr><td>CR73_22</td><td>BibArticle</td><td>Rabbani SA, Gladu J, Harakidas P, Jamison B, Goltzman D. Over-production of parathyroid hormone-related peptide results in increased osteolytic skeletal metastasis by prostate cancer cells in vivo. Int J Cancer 1999;80:257&#8211;64.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1002/(SICI)1097-0215(19990118)80:2%3C257::AID-IJC15%3E3.3.CO;2-V>10.1002/(SICI)1097-0215(19990118)80:2%3C257::AID-IJC15%3E3.3.CO;2-V</a></td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_2, Author_FamilyName_1, FirstPage, Year</td><td>CrossRef</td></tr><tr><td>CR74_22</td><td>BibArticle</td><td>Lu Y, Xiao G, Galson DL, et al. PTHrP-induced MCP-1 production by human bone marrow endothelial cells and osteoblasts promotes osteoclast differentiation and prostate cancer cell proliferation and invasion in vitro. Int J Cancer 2007;121(4):724&#8211;33.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR75_22</td><td>BibChapter</td><td>Sehgal P, Wang L, Rayanade R, Pan H, Margulies L. Interleukin-6 type cytokines. In: Mackiewicz A, Koji A, Sehgal P, eds. Annals of the New York Academy of Sciences. New York: New York Academy of Sciences; 1995:1&#8211;14.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR76_22</td><td>BibArticle</td><td>Hirano T. The biology of interleukin-6. Chem Immunol 1992;51:153&#8211;80.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1159/000420758>10.1159/000420758</a></td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR77_22</td><td>BibChapter</td><td>Taga T, Hibi M, Murakami M, et al. Interleukin-6 receptor and signals. In: Kishimoto T, ed. Interleukins: Molecular Biology and Immunology, Chem Immunol. Basel: Karger; 1992:181&#8211;204.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR78_22</td><td>BibArticle</td><td>Mullberg J, Oberthur W, Lottspeich F, et al. The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. J Immunol 1994;152:4958&#8211;68.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR79_22</td><td>BibArticle</td><td>Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J 1994;300:281&#8211;90.</td><td><a href=http://dx.doi.org/10.1042/bj3000281>10.1042/bj3000281</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Year, ArticleTitle, Author_FamilyName_1, VolumeID, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR80_22</td><td>BibArticle</td><td>Lust JA, Donovan KA, Kline MP, Greipp PR, Kyle RA, Maihle NJ. Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine 1992;4:96&#8211;100.</td><td><a href=http://dx.doi.org/10.1016/1043-4666(92)90043-Q>10.1016/1043-4666(92)90043-Q</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_2, Author_FamilyName_1, JournalTitle, ArticleTitle, FirstPage, Year</td><td>CrossRef</td></tr><tr><td>CR81_22</td><td>BibArticle</td><td>Mackiewicz A, Schooltink H, Heinrich PC, Rose-John S. Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol 1992;149:2021&#8211;7.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR82_22</td><td>BibArticle</td><td>Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 1999;161:182&#8211;7.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR83_22</td><td>BibArticle</td><td>Hoosien N, Abdul M, McCabe R, et al. Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer. Urol Oncol 1995;1:246&#8211;51.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1016/1078-1439(96)00012-9>10.1016/1078-1439(96)00012-9</a></td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_2, FirstPage, Year, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR84_22</td><td>BibArticle</td><td>Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, Simons JW. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 1995;45:542&#8211;9.</td><td><a href=http://dx.doi.org/10.1016/S0090-4295(99)80034-X>10.1016/S0090-4295(99)80034-X</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, VolumeID, JournalTitle, Author_FamilyName_1, ArticleTitle, Year, FirstPage</td><td>CrossRef</td></tr><tr><td>CR85_22</td><td>BibArticle</td><td>Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 1999;41:127&#8211;33.</td><td><a href=http://dx.doi.org/10.1002/(SICI)1097-0045(19991001)41:2%3C127::AID-PROS7%3E3.0.CO;2-H>10.1002/(SICI)1097-0045(19991001)41:2%3C127::AID-PROS7%3E3.0.CO;2-H</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, FirstPage, Year, Author_FamilyName_2, VolumeID, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR86_22</td><td>BibArticle</td><td>Tsingotjidou AS, Zotalis G, Jackson KR, et al. Development of an animal model for prostate cancer cell metastasis to adult human bone. Anticancer Res 2001;21:971&#8211;8.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR87_22</td><td>BibArticle</td><td>Siegsmund MJ, Yamazaki H, Pastan I. Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia. J Urol 1994;151:1396&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR88_22</td><td>BibArticle</td><td>Hobisch A, Rogatsch H, Hittmair A, et al. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol 2000;191:239&#8211;44.</td><td><a href=http://dx.doi.org/10.1002/1096-9896(2000)9999:9999%3C::AID-PATH633%3E3.0.CO;2-X>10.1002/1096-9896(2000)9999:9999%3C::AID-PATH633%3E3.0.CO;2-X</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, FirstPage, Year, Author_FamilyName_2, VolumeID, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR89_22</td><td>BibArticle</td><td>Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty [In Process Citation]. Annu Rev Med 2000;51:245&#8211;70.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR90_22</td><td>BibArticle</td><td>Jilka RL, Passeri G, Girasole G, et al. Estrogen loss upregulates hematopoiesis in the mouse: a mediating role of IL-6. Exp Hematol 1995;23:500&#8211;6.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR91_22</td><td>BibArticle</td><td>O&#8217;Brien CA, Lin SC, Bellido T, Manolagas SC. Expression levels of gp130 in bone marrow stromal cells determine the magnitude of osteoclastogenic signals generated by IL-6-type cytokines. J Cell Biochem 2000;79:532&#8211;41.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1002/1097-4644(20001215)79:4&lt;532::aid-jcb20&gt;3.0.co;2-u>10.1002/1097-4644(20001215)79:4&lt;532::aid-jcb20&gt;3.0.co;2-u</a></td><td><b></b></td>
<td>Year</td><td>CrossRef</td></tr><tr><td>CR92_22</td><td>BibArticle</td><td>Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin- 6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999;25:255&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR93_22</td><td>BibArticle</td><td>Greenfield EM, Shaw SM, Gornik SA, Banks MA. Adenyl cyclase and interleukin 6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption. J Clin Invest 1995;96:1238&#8211;44.</td><td><a href=http://dx.doi.org/10.1172/JCI118157>10.1172/JCI118157</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, FirstPage, Year, VolumeID, Author_FamilyName_2, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR94_22</td><td>BibArticle</td><td>de la Mata J, Uy HL, Guise TA, et al. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest 1995;95:2846&#8211;52.</td><td><a href=http://dx.doi.org/10.1172/JCI117990>10.1172/JCI117990</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, FirstPage, Year, VolumeID, Author_FamilyName_2, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR95_22</td><td>BibArticle</td><td>Smith PC, Keller ET. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate 2001;48:47&#8211;53.</td><td><a href=http://dx.doi.org/10.1002/pros.1080>10.1002/pros.1080</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, FirstPage, ArticleTitle, Author_FamilyName_1, Author_FamilyName_2, VolumeID</td><td>CrossRef</td></tr><tr><td>CR96_22</td><td>BibArticle</td><td>Bentley H, Hamdy FC, Hart KA, et al. Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 1992;66:1159&#8211;63.</td><td><a href=http://dx.doi.org/10.1038/bjc.1992.427>10.1038/bjc.1992.427</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_2, JournalTitle, Author_FamilyName_1, ArticleTitle, FirstPage, Year</td><td>CrossRef</td></tr><tr><td>CR97_22</td><td>BibArticle</td><td>Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1:944&#8211;9.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1038/nm0995-944>10.1038/nm0995-944</a></td><td><b>CrossRef-Meta</b></td>
<td>Year, FirstPage, VolumeID, Author_FamilyName_2, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR98_22</td><td>BibArticle</td><td>Nelson JB, Carducci MA. The role of endothelin-1 and endothelin receptor antagonists in prostate cancer. BJU Int 2000;85(Suppl 2):45&#8211;8.</td><td><a href=http://dx.doi.org/10.1046/j.1464-410X.2000.00063.x>10.1046/j.1464-410X.2000.00063.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Year, ArticleTitle, Author_FamilyName_1, VolumeID, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR99_22</td><td>BibArticle</td><td>LeRoy BE, Sellers RS, Rosol TJ. Canine prostate stimulates osteoblast function using the endothelin receptors. Prostate 2004;59:148&#8211;56.</td><td><a href=http://dx.doi.org/10.1002/pros.10370>10.1002/pros.10370</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, VolumeID, Author_FamilyName_1, ArticleTitle, FirstPage, Year</td><td>CrossRef</td></tr><tr><td>CR100_22</td><td>BibArticle</td><td>Jimeno A, Carducci M. Atrasentan: targeting the endothelin axis in prostate cancer. Expert Opin Investig Drugs 2004;13:1631&#8211;40.</td><td><a href=http://dx.doi.org/10.1517/13543784.13.12.1631>10.1517/13543784.13.12.1631</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, VolumeID, Author_FamilyName_1, ArticleTitle, FirstPage, Year</td><td>CrossRef</td></tr><tr><td>CR101_22</td><td>BibArticle</td><td>Pirtskhalaishvili G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate 2000;44:77&#8211;87.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1002/1097-0045(20000615)44:1%3C77::AID-PROS10%3E3.3.CO;2-7>10.1002/1097-0045(20000615)44:1%3C77::AID-PROS10%3E3.3.CO;2-7</a></td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Year, Author_FamilyName_2, VolumeID, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR102_22</td><td>BibArticle</td><td>Perkel VS, Mohan S, Baylink DJ, Linkhart TA. An inhibitory insulin-like growth factor binding protein (In-IGFBP) from human prostatic cell conditioned medium reveals N-terminal sequence identity with bone derived In-IGFBP. J Clin Endocrinol Metabol 1990;71:533&#8211;5.</td><td><a href=http://dx.doi.org/10.1210/jcem-71-2-533>10.1210/jcem-71-2-533</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_2, Author_FamilyName_1, ArticleTitle, Year, FirstPage</td><td>CrossRef</td></tr><tr><td>CR103_22</td><td>BibArticle</td><td>Taguchi Y, Yamamoto M, Yamate T, et al. Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage. Proc Assoc Am Physicians 1998;110:559&#8211;74.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR104_22</td><td>BibArticle</td><td>Le Brun G, Aubin P, Soliman H, et al. Upregulation of endothelin 1 and its precursor by IL-1beta, TNF-alpha, and TGF-beta in the PC3 human prostate cancer cell line. Cytokine 1999;11:157&#8211;62.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR105_22</td><td>BibArticle</td><td>Guise TA. Molecular mechanisms of osteolytic bone metastases. Cancer 2000;88:2892&#8211;8.</td><td><a href=http://dx.doi.org/10.1002/1097-0142(20000615)88:12+%3C2892::AID-CNCR2%3E3.0.CO;2-Y>10.1002/1097-0142(20000615)88:12+%3C2892::AID-CNCR2%3E3.0.CO;2-Y</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_1, JournalTitle, ArticleTitle, Year, FirstPage</td><td>CrossRef</td></tr><tr><td>CR106_22</td><td>BibArticle</td><td>Karaplis AC, Vautour L. Parathyroid hormone-related peptide and the parathyroid hormone/parathyroid hormone-related peptide receptor in skeletal development. Curr Opin Nephrol Hypertens 1997;6:308&#8211;13.</td><td><a href=http://dx.doi.org/10.1097/00041552-199707000-00002>10.1097/00041552-199707000-00002</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, FirstPage, Year, Author_FamilyName_2, VolumeID, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR107_22</td><td>BibArticle</td><td>Killian CS, Corral DA, Kawinski E, Constantine RI. Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun 1993;192:940&#8211;7.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR108_22</td><td>BibArticle</td><td>Goltzman D, Karaplis AC, Kremer R, Rabbani SA. Molecular basis of the spectrum of skeletal complications of neoplasia. Cancer 2000;88:2903&#8211;8.</td><td><a href=http://dx.doi.org/10.1002/1097-0142(20000615)88:12+%3C2903::AID-CNCR4%3E3.0.CO;2-G>10.1002/1097-0142(20000615)88:12+%3C2903::AID-CNCR4%3E3.0.CO;2-G</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, FirstPage, Year, Author_FamilyName_2, VolumeID, JournalTitle, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR109_22</td><td>BibArticle</td><td>Dai J, Kitagawa Y, Zhang J, et al. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res 2004;64:994&#8211;9.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-03-1382>10.1158/0008-5472.CAN-03-1382</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, VolumeID, FirstPage, Year, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR110_22</td><td>BibArticle</td><td>Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 2005;65:7554&#8211;60.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></table>